Search

Your search keyword '"Morisco F"' showing total 6 results
Start Over Author "Morisco F" Journal gut
6 results on '"Morisco F"'

1. Apple polyphenol extracts prevent damage to human gastric epithelial cells in vitro and to rat gastric mucosa in vivo

Author

Graziani, G, D'Argenio, Tuccillo, C, Loguericio, C, Ritieni, A, Morisco, F, Del Vecchio Blanco, C, Fogliano, V, and Roamno, M

Subjects
Phytochemicals -- Prevention, Phytochemicals -- Research, Gastric mucosa -- Care and treatment, Gastric mucosa -- Research, Apple juice -- Prevention, Apple juice -- Research, Antioxidants -- Prevention, Antioxidants -- Research, Health
Published
2005

2. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. (Liver Disease)

Author

Camma, C., Bruno, S., Schepis, F., Iacono, O. Lo, Andreone, P., Gramenzi, A.G., Mangia, A., Andriulli, A., Puoti, M., Spadaro, A., Freni, M., Marco, V. Di, Cino, L., Saracco, G., Chiesa, A., Crosignani, A., Caporaso, N., Morisco, F., Rumi, M.G., and Craxi, A.

Subjects
Interferon -- Evaluation, Ribavirin -- Evaluation, Hepatitis C -- Drug therapy, Health
Abstract

Background and aims: Retreatment with a combination of α interferon (IFN) plus ribavirin of patients with chronic hepatitis C who did not respond to IFN monotherapy has not been assessed [...]

Published
2002

3. Necrosis in hepatocellular carcinomas of explanted livers following loco-regional treatment before liver transplantation: association with tumour recurrence

Author

Morisco, F., Stigliano, R., Quaglia, A., and Leandro, G.

Subjects
Liver -- Transplantation, Hepatoma -- Care and treatment -- Research, Necrosis -- Research -- Care and treatment, Health, Care and treatment, Research, Health aspects
Abstract

Introduction: All types of local ablation therapy (TACE, TAE, PEI, RFA, MCT, etc) produce necrosis of hepatocellular carcinomas (HCC) but the size and pattern of necrosis and possible prognostic significance [...]

Published
2004

4. Hepatocellular carcinoma treated by orthotopic liver transplantation: prediction for recurrence

Author

Grasso, A., Stigliano, R., Morisco, F., Quaglia, A., Dhillon, P., Davidson, B., Rolles, K., Patch, D., and Burroughs, A.K.

Subjects
Liver -- Transplantation, Hepatoma -- Care and treatment -- Research, Health, Care and treatment, Research
Abstract

Background: Although liver transplantation (LT) for hepatocellular carcinoma (HCC) can be curative a 25% recurrence by 5 years is limiting. Aim: Evaluate predictive factors for HCC recurrence after LT. Patients [...]

Published
2004

5. Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy

Author

Stigliano, R., Morisco, F., Rolando, N., Cecilioni, L., Sharma, D., Davidson, B., Rolles, K., Burroughs, A.K., and Patch, D.

Subjects
Mortality -- Comparative analysis -- United Kingdom, Liver -- Transplantation, Health, Research, Comparative analysis, Health aspects
Abstract

Introduction: Older age is not considered a contraindication for liver transplantation, but age related morbidity may be a cause of mortality. Aim: To evaluate survival and the incidence of main [...]

Published
2004

6. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.

Author

Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, and Farinati F

Subjects
Male, Humans, Risk Factors, Carcinoma, Hepatocellular epidemiology, Carcinoma, Hepatocellular etiology, Carcinoma, Hepatocellular diagnosis, Liver Neoplasms epidemiology, Liver Neoplasms etiology, Liver Neoplasms diagnosis, Non-alcoholic Fatty Liver Disease complications
Abstract

Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum of liver diseases associated to metabolic disorders. The main objective of this study was to compare patients with MAFLD and non-MAFLD with hepatocellular carcinoma (HCC) included in a nationally representative cohort., Methods: We analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 by 23 Italian Liver Cancer centres to compare epidemiological and future trends in three subgroups: pure, single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD); and non-MAFLD HCC., Results: MAFLD was diagnosed in the majority of patients with HCC (68.4%). The proportion of both total MAFLD and S-MAFLD HCC significantly increased over time (from 50.4% and 3.6% in 2002-2003, to 77.3% and 28.9% in 2018-2019, respectively, p<0.001). In Italy S-MAFLD HCC is expected to overcome M-MAFLD HCC in about 6 years. Patients with S-MAFLD HCC were older, more frequently men and less frequently cirrhotic with clinically relevant portal hypertension and a surveillance-related diagnosis. They had more frequently large tumours and extrahepatic metastases. After weighting, and compared with patients with non-MAFLD, S-MAFLD and M-MAFLD HCC showed a significantly lower overall (p=0.026, p=0.004) and HCC-related (p<0.001, for both) risk of death. Patients with S-MAFLD HCC showed a significantly higher risk of non-HCC-related death (p=0.006)., Conclusions: The prevalence of MAFLD HCC in Italy is rapidly increasing to cover the majority of patients with HCC. Despite a less favourable cancer stage at diagnosis, patients with MAFLD HCC have a lower risk of HCC-related death, suggesting reduced cancer aggressiveness., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results